H2AC6

H2AC6 (HIST1H2AC/H2AFL) is a replication-dependent histone H2A isoform whose expression level exerts isoform-specific, non-redundant control over cell proliferation (PMID:23956221, PMID:36358254). Its abundance is functionally consequential rather than interchangeable with other H2A variants: siRNA knockdown in bladder cancer cells increases proliferation and tumorigenicity, identifying a proliferation-restraining role (PMID:23956221), while its reduced relative abundance in chronic lymphocytic leukemia chromatin marks differential isoform usage in malignancy (PMID:19253275). In a distinct cellular context, CRISPR activation in THP-1 cells increases proliferation and places H2AC6 expression downstream of the NRAS-MEK signaling axis, with knockdown reducing proliferation and MEK inhibition lowering its expression (PMID:36358254). H2AC6 is subject to layered isoform-specific post-transcriptional regulation: discrete 5' UTR elements confer translational repression (PMID:23956221), and the locus undergoes regulated alternative polyadenylation during differentiation and after ionizing radiation, with polyadenylated transcripts exported to the cytoplasm and loaded onto polyribosomes (PMID:23717473). The molecular basis by which H2AC6 incorporation into chromatin produces these proliferative outcomes has not been characterized in the available corpus.

1. 2009 Medium

   Established that a specific H2A isoform's abundance, not just bulk histone content, is altered in a malignancy, raising the question of isoform-specific function.

   Evidence Quantitative LC-MS proteomic profiling of primary CLL cells versus normal B cells across a 40-patient cohort

   PMID:19253275

   Open questions at the time

   • Does not establish whether reduced H2AC6 abundance is causal or consequential in CLL
   • No mechanism linking isoform abundance to chromatin state or transcription
2. 2013 Medium

   Showed that H2AC6 abundance is functionally non-redundant by demonstrating that lowering it accelerates proliferation, and identified a post-transcriptional control point in its 5' UTR.

   Evidence siRNA knockdown with proliferation/tumorigenicity assays plus 5' UTR translational reporter analysis in bladder cancer cells

   PMID:23956221

   Open questions at the time

   • Mechanism by which the isoform restrains proliferation is unknown
   • 5' UTR trans-acting factors not identified
   • Single cancer-cell context
3. 2013 Medium

   Revealed that the H2AC6 locus is regulated by alternative 3' end processing tied to differentiation and DNA damage, with polyadenylated transcripts entering cytoplasmic translation.

   Evidence qRT-PCR for polyadenylated vs. stem-loop transcripts and polyribosome fractionation in differentiating mesenchymal/osteoblast models and after ionizing radiation

   PMID:23717473

   Open questions at the time

   • Functional consequence of the polyadenylated isoform versus the stem-loop form is unresolved
   • Polyadenylation machinery and signals not defined
4. 2022 Medium

   Positioned H2AC6 expression within an oncogenic signaling pathway, showing its proliferative output is wired downstream of NRAS-MEK.

   Evidence CRISPR activation screening, doxycycline-inducible NRAS, MEK inhibitor epistasis, and siRNA knockdown with proliferation assays in THP-1 cells

   PMID:36358254

   Open questions at the time

   • Direction of the proliferative effect (activation increases proliferation here vs. knockdown increasing it in bladder cells) is context-dependent and unreconciled
   • No direct transcriptional link from MEK to the H2AC6 promoter shown

• How H2AC6 incorporation into nucleosomes mechanistically alters chromatin to control proliferation, and why its directional effect differs across cell types, remains unresolved.
• No structural or chromatin-incorporation mechanism characterized
• No identified chromatin readers or modifying enzymes specific to this isoform
• Context-dependence between tumor types unexplained